
# UK Approach to Clinical Research during the COVID-19 Pandemic

Kate Gerrand – UK Department of Health and Social Care Dr Mike Rogers – National Institute for Health and Care Research

#### **Overview**


- Introduction to the National Institute of Health and Care Research
- Overview of NIHR's response to COVID-19
- Working with UKRI to fund research into COVID-19
- Prioritising clinical research resources to deliver COVID-19 research
- Key examples of success
- Future plans







# NIHR's mission is to improve the health and wealth of the nation through research.




Funding high quality, timely research that benefits the National Health Service, public health and social care Investing in world class expertise, facilities and a skilled delivery workforce to translate discoveries into improved treatments and services

Partnering with patients, service users, carers and communities improving the relevance, quality and impact of our research


Attracting, training and supporting the best researchers to tackle complex health and social care challenges Collaborating
with other public
funders, charities
and industry to
shape a cohesive
and globally
competitive
research system

Funding applied global health research and training to meet the needs of the poorest people in low and middle income countries





### Our research programmes



We have eleven research programmes that fund multi-disciplinary health and social care research in both clinical and non-clinical settings to meet a range of evidence priorities. We offer both commissioned (i.e. opportunities for funding in specific topics) and researcher-led funding opportunities.

Funding of large clinical trials is typically undertaken through the Efficacy and Mechanism Evaluation (EME, earlier phase) and Health Technology Assessment (HTA, later phase) programmes



### NIHR response to COVID pandemic

#### Our response to the pandemic



Finding new treatments



**Developing vaccines and prevention** 



Informing policy and decision-making







- Supported more than 2 million people to participate in COVID-19 studies
- Pre-existing infrastructure underpinned all areas of response
- New ways of working: decentralised trials, remote patient monitoring

NIHR's response to COVID-19 | NIHR



# Funding research during the COVID pandemic required a different approach to that of business as usual



#### Speed

Normal programme timelines not designed to accommodate rapidly changing acute situation

Requirement to deliver impact, rapidly



#### **Volume of information**

Usual process very robust in terms of information required

Not realistic when rapid application process is required



#### Remit

Time taken by researchers to consider which funder, programme and scheme to apply to



# Working with UKRI (Medical Research Council), we developed COVID-specific funding opportunities to address research questions during the acute phase of the pandemic (1)

#### **COVID-19 Rapid Response Call**

Launched 4 February 2020

Call 1 - Active intervention development (Vaccines and therapeutics)

Call 2 - Diagnosing and understanding COVID-19 (Other key areas)

26 awards (£24.2M) made Including RECOVERY,PRINCIPLE, clinical development of Oxford vaccine

#### **Key points**



**Speed** – call 1 window for applications 9 days; for call 2, 23 days



**Volume** – 271 applications received across the 2 calls



Less **information required** in the application than standard schemes



Single entry point for researchers working anywhere within NIHR and MRC remit



**Impact** expected within 18 months



# Working with UKRI (Medical Research Council), we developed COVID-specific funding opportunities to address research questions during the acute phase of the pandemic (2)

#### **COVID-19 Rolling Call**

April - June 2020

# Remit covering span of MRC and NIHR remits, including:

Virology, Immunity and Pathophysiology
Diagnostics
Epidemiology
Mental Health
Clinical Management
Primary, Adjunctive and Supportive Therapies
Vaccines
Health and Care Delivery
Underpinning tech

51 awards made - ~£40M Including PHOSP, COVID-NURSE, REACH, key vaccine comparison study, social care research

#### Key points







Retained **short application** and **single entry point**, **and** instituted **link with prioritisation** of NIHR clinical research resources



Applications reviewed when submitted



Use of college of experts and peer review as **triage** mechanism for **weekly funding panel** 



Patient and public involvement throughout



**Impact** expected within 12 months



High **volume** – over 700 applications considered




**Highlight notices** in key topics



# The Clinical Research Network/ Research Delivery Network

- Provides research delivery staff and services in the NHS and wider health and care system in England to deliver funded research – distributes approximately £350 million in funding from DHSC via the 15 Local Clinical Research Networks (LCRNs) for NHS Support Costs to research delivery organisations (NHS trusts, primary care and non-NHS settings)
- Supports a portfolio of approx. 4000 eligible studies under 30 Specialties in the NHS and wider health and care system
- Consists of the coordinating centre and 15 LCRNs, hosted by NHS trusts across England
- Has been an essential part of UK research infrastructure which has seen huge progress since 2015, supporting a transformation in the strength of England's research delivery system, and underpinning huge expansion of research participation.
- Throughout 24/25, the CRN is transitioning to the NIHR Research Delivery Network (RDNCC and 12 RRDNs), to build on the success of the CRN and address government priorities and drivers for change in the health and care research landscape





# NIHR's Clinical Research Network (now Research Delivery Network) developed a prioritisation process to ensure resources were directed towards highest priority clinical research studies— <u>Urgent Public Health Designation</u>


The NIHR CRN (currently transitioning to RDN) provides infrastructure (research support staff and services) in the NHS and wider health and care system in England to deliver funded research, across all conditions and settings



#### The UPH 4-Step Process



#### No. Applications Received by Week





### World-leading, streamlined COVID-19 trials






Randomised Evaluation of COVID-19 Therapy



### **PANORAMIC**


Platform Adaptive trial of NOvel antiviRals for eArly treatMent of COVID-19 In the Community



### REMAP-CAP

Randomized, Embedded, Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia






## **UK COVID-19 treatment study saved 1 million lives**

- Starting in March 2020, the RECOVERY study was funded to evaluate repurposed treatments for patients hospitalised with COVID-19.
- UK Clinical Research Network enabled recruitment of 47,000 patients across 175 UK hospitals.
- NHS was immediately authorised to use dexamethasone from June 2020.
- Provided a model for future platform studies.





## **Embedding the learning from the COVID-19 pandemic**

Developing a cross-UK research funders framework for research for pandemic preparedness and response including

- Commissioning inter-pandemic research
- "Hibernated" studies
- Rapid evaluation and evidence synthesis
- Study prioritisation plans
- Public and patient involvement
- Flexible capability to respond

Independent report

Commercial clinical trials in the UK: the Lord O'Shaughnessy review - final report

Policy paper

The Future of Clinical Research Delivery: 2022 to 2025 implementation plan

Published 30 June 2022













# For further information:

kate.gerrand@dhsc.gov.uk mike.rogers@nihr.ac.uk

